<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HB93E395EF5594E66A3FB8D4E00991372" public-private="public">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>110 HR 1560 IH: Alzheimer’s Breakthrough Act of
</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2007-03-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
	<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>110th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1560</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20070319">March 19, 2007</action-date>
			<action-desc><sponsor name-id="M000133">Mr. Markey</sponsor> (for
			 himself and <cosponsor name-id="S000522">Mr. Smith of New Jersey</cosponsor>)
			 introduced the following bill; which was referred to the
			 <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Public Health Service Act to fund
		  breakthroughs in Alzheimer’s disease research while providing more help to
		  caregivers and increasing public education about prevention.</official-title>
	</form>
	<legis-body id="H3F2F0F3AD44841568E4CD8C3A521D5B3" style="OLC">
		<section display-inline="no-display-inline" id="H0886C6C113AB4A11814F1456322BD643" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Alzheimer’s Breakthrough Act of
			 2007</short-title></quote>.</text>
		</section><section id="H0152EE135988499E9F828549E8E30027"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress makes the following
			 findings:</text>
			<paragraph id="HBBEC2DE7FADE4D7E948795D0148C9080"><enum>(1)</enum><text>Alzheimer's
			 disease is a disorder that destroys cells in the brain. The disease is the
			 leading cause of dementia, a condition that involves gradual memory loss,
			 decline in the ability to perform routine tasks, disorientation, difficulty in
			 learning, loss of language skills, impairment of judgment, and personality
			 changes. As the disease progresses, people with Alzheimer's disease become
			 unable to care for themselves. The loss of brain cells eventually leads to the
			 failure of other systems in the body.</text>
			</paragraph><paragraph id="HB0F34D1E9FA94B08B7FBEF6446FAA611"><enum>(2)</enum><text>An estimated
			 4,500,000 Americans have Alzheimer's disease and 1 in 10 individuals have a
			 family member with the disease. By 2050, the number of individuals with the
			 disease could range from 13,000,000 to 16,000,000 unless science finds a way to
			 prevent or cure the disease.</text>
			</paragraph><paragraph id="HA0591C5842AB471FA3E8E5ABAFF8B721"><enum>(3)</enum><text>One in 10 people
			 over the age of 65, and nearly half of those over the age of 85 have
			 Alzheimer's disease. Younger people also get the disease.</text>
			</paragraph><paragraph id="H30950DB21FB74465AFC81B4E00C2ACDA"><enum>(4)</enum><text>The Alzheimer's
			 disease process may begin in the brain as many as 20 years before the symptoms
			 of Alzheimer's disease appear. An individual will live an average of 8 years
			 and as many as 20 once the symptoms of Alzheimer's disease appear.</text>
			</paragraph><paragraph id="HECD7929990FE4E3D821C4DEF69AD5C7"><enum>(5)</enum><text>The average
			 lifetime cost of care for an individual with Alzheimer's disease is
			 $170,000.</text>
			</paragraph><paragraph id="H825430F8132940ABAC733859FD29F610"><enum>(6)</enum><text>In 2005, Medicare
			 alone spent $91,000,000,000 for the care of individuals with Alzheimer's
			 disease and this amount is projected to increase to $160,000,000,000 in
			 2010.</text>
			</paragraph><paragraph id="H32B2BD0828E04E09A95D00E42192916F"><enum>(7)</enum><text>Ninety-five
			 percent of Medicare beneficiaries with Alzheimer’s disease have one or more
			 other chronic conditions that are common in the elderly, coronary heart disease
			 (30 percent), congestive heart failure (28 percent), diabetes (21 percent), and
			 chronic obstructive pulmonary disease (17 percent).</text>
			</paragraph><paragraph id="H9EF66F16566B4D338EA4AADBD643BF84"><enum>(8)</enum><text>Seven in 10
			 individuals with Alzheimer's disease live at home. While almost 75 percent of
			 home care is provided by family and friends, the average annual cost of paid
			 care for people with Alzheimer's disease at home is $19,000 per year. Almost
			 all families pay this cost out of pocket.</text>
			</paragraph><paragraph id="HE3B933C0306C4758B1F54488F2CCA2F4"><enum>(9)</enum><text>Half of all
			 nursing home residents have Alzheimer's disease or a related disorder. The
			 average annual cost of Alzheimer's disease nursing home care is more than
			 $70,000. Medicaid pays half of the total nursing home bill and helps 2 out of 3
			 residents pay for their care. Medicaid expenditures for nursing home care for
			 people with Alzheimer's disease are estimated to increase from $21,000,000,000
			 in 2005 to $24,000,000,000 in 2010.</text>
			</paragraph><paragraph id="HAC61FB88FBDA4A3AA8A28BFF7B375190"><enum>(10)</enum><text>In fiscal year
			 2007, the Federal Government will spend an estimated $642,000,000 on
			 Alzheimer's disease research. If the United States achieves its research goals
			 (preventing the onset of Alzheimer's disease in those at risk and treating and
			 delaying progression of the disease in those who have symptoms), annual
			 Medicare savings would be $51,000,000,000 by 2015 and $88,000,000,000 by 2020.
			 Annual Medicaid savings would be $10,000,000,000 in 2015 and $17,000,000,000 by
			 2020 and the projected number of cases of Alzheimer's disease can be reduced by
			 40 percent by the middle of the century.</text>
			</paragraph><paragraph id="H0955AACCF9784E2E938D971630A33EC9"><enum>(11)</enum><text>An analysis by
			 the Montefiore Medical Center and the Albert Einstein College of Medicine
			 estimated that the annual value of the informal care system is
			 $306,000,000,000. Family caregiving comes at enormous physical, emotional, and
			 financial sacrifice, putting the whole system at risk.</text>
			</paragraph><paragraph id="HAF188F7C11634647A33B2D365C9C0337"><enum>(12)</enum><text>One in 8
			 Alzheimer's disease caregivers becomes ill or injured as a direct result of
			 caregiving. One in 3 uses medication for problems related to caregiving. Older
			 caregivers are 3 times more likely to become clinically depressed than others
			 in their age group.</text>
			</paragraph><paragraph id="H416C810AEF144F5D008CB9003B0046CF"><enum>(13)</enum><text>Elderly spouses
			 strained by caregiving are 63 percent more likely to die during a given 4-year
			 period than other spouses their age.</text>
			</paragraph><paragraph id="H676ED33820F04B2B9FE267F451D4FC4"><enum>(14)</enum><text>Almost 3 of 4
			 caregivers are women. One in 3 has children or grandchildren under the age of
			 18 living at home. Caregiving leaves them less time for other family members
			 and they are much more likely to report family conflicts because of their
			 caregiving role.</text>
			</paragraph><paragraph id="H19A0AEB9A3044BCC8C0220B7CB304F9B"><enum>(15)</enum><text>Most Alzheimer's
			 disease caregivers work outside the home before beginning their caregiving
			 careers, but caregiving forces them to miss work, cut back to part-time, take
			 less demanding jobs, choose early retirement, or give up work altogether. As a
			 result, in 2002, Alzheimer's disease cost American business an estimated
			 $36,500,000,000 in lost productivity, as well as an additional $24,600,000,000
			 in business contributions to the total cost of care.</text>
			</paragraph></section><title id="HDD4B0BFA6C1C441EB59E2253ED1BF029"><enum>I</enum><header>Increasing the
			 Federal commitment to alzheimer’s research</header>
			<section id="HBE1A1456F5904053B1E8D7BE457FFC"><enum>101.</enum><header>Doubling nih
			 funding for Alzheimer’s disease research</header><text display-inline="no-display-inline">For the purpose of conducting and supporting
			 research on Alzheimer’s disease (including related activities under subpart 5
			 of part C of title IV of the <act-name parsable-cite="PHSA">Public Health
			 Service Act</act-name> (<external-xref legal-doc="usc" parsable-cite="usc/42/285e">42 U.S.C. 285e et seq.</external-xref>)), there are authorized to be
			 appropriated $1,300,000,000 for fiscal year 2008, and such sums as may be
			 necessary for each of fiscal years 2009 through 2012.</text>
			</section><section id="HB797B82D432A423500B82E72D7688C6F"><enum>102.</enum><header>Priority to
			 Alzheimer’s disease research</header><text display-inline="no-display-inline">Section 443 of the
			 <act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
			 285e) is amended—</text>
				<paragraph id="H2A2ABD0D8E704E068706D66EA6B3BCA"><enum>(1)</enum><text>by
			 striking <quote>The general</quote> and inserting <quote>(a)<header-in-text level="subsection" style="OLC"> In general</header-in-text>.—The
			 general</quote>; and</text>
				</paragraph><paragraph id="H235568FCA2F24A4182C3BC28664392D"><enum>(2)</enum><text>by
			 adding at the end the following:</text>
					<quoted-block id="H4F9BC352332F4D84BC60E10070DC85E5" style="OLC">
						<subsection id="H4899E33ABF0444348598A8BC23E8ED56"><enum>(b)</enum><header>Priorities</header><text>The
				Director of the Institute shall, in expending amounts appropriated to carry out
				this subpart, give priority to conducting and supporting Alzheimer’s disease
				research.</text>
						</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></section><section id="H1E4F19A68CBF4E8B9701F621F7BF4D5"><enum>103.</enum><header>Alzheimer's
			 disease prevention initiative</header><text display-inline="no-display-inline">Section 443 of the
			 <act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
			 285e), as amended by section 102, is further amended by adding at the end the
			 following:</text>
				<quoted-block display-inline="no-display-inline" id="HE4B1FCBC90B84D83844925B9F9DD9D44" style="OLC">
					<subsection id="HEE9A1ADBE87A4D458967362E5D8D3041"><enum>(c)</enum><header>Prevention
				trials</header><text>The Director of the Institute shall increase the emphasis
				on the need to conduct Alzheimer's disease prevention trials within the
				National Institutes of Health.</text>
					</subsection><subsection id="HF39D1E33AF1949C381106E6B737D00B8"><enum>(d)</enum><header>Neuroscience
				initiative</header><text>The Director of the Institute shall ensure that
				Alzheimer’s disease is maintained as a high priority for the existing
				neuroscience
				initiative.</text>
					</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
			</section><section id="HFFD29AB696354B59916D47B09FC1F640"><enum>104.</enum><header>Alzheimer’s
			 disease clinical research</header>
				<subsection id="H3F11FEB218184E8B96B0034BF70037E8"><enum>(a)</enum><header>Clinical
			 Research</header><text>Subpart 5 of part C of title IV of the
			 <act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
			 285e et seq.) is amended by adding at the end the following:</text>
					<quoted-block act-name="Public Health Service Act" id="H6E9AA890C7EF4CA09B005F215185A481" style="OLC">
						<section id="HCCA3BF3120434CF68445B1B11E7F5C83"><enum>445J.</enum><header>Alzheimer’s
				disease clinical research</header>
							<subsection id="HDFDB4D822B434DA0A4AB37A434D1DB56"><enum>(a)</enum><header>In
				General</header><text>The Director of the Institute, pursuant to section
				444(d), shall conduct and support cooperative clinical research regarding
				Alzheimer’s disease. Such research shall include—</text>
								<paragraph id="HD59B389D8F744F2A94CD0000576964CD"><enum>(1)</enum><text>investigating
				therapies, interventions, and agents to detect, treat, slow the progression of,
				or prevent Alzheimer’s disease;</text>
								</paragraph><paragraph id="H87A2A8C7553E4AEA97D105E3EDED348D"><enum>(2)</enum><text>enhancing the
				national infrastructure for the conduct of clinical trials;</text>
								</paragraph><paragraph id="H1BF2704F4DC44FDE82CAFC875DA7768"><enum>(3)</enum><text>developing and
				testing novel approaches to the design and analysis of such trials;</text>
								</paragraph><paragraph id="H7E622629F4E848689D61E64F1E66AB40"><enum>(4)</enum><text>facilitating the
				enrollment of patients for such trials, including patients from diverse
				populations;</text>
								</paragraph><paragraph id="H8BFB4AF2AF3F4EC782D7A461088F1D5C"><enum>(5)</enum><text>developing
				improved diagnostics and means of patient assessment for Alzheimer’s
				disease;</text>
								</paragraph><paragraph id="H01DD483C32ED445C828DAD43D9E85CE4"><enum>(6)</enum><text>the conduct of
				clinical trials on potential therapies, including readily available compounds
				such as herbal remedies and other alternative treatments;</text>
								</paragraph><paragraph id="H5A04FB53FA51422798B409F288EE9482"><enum>(7)</enum><text>research to
				develop better methods of early diagnosis, including the use of current imaging
				techniques; and</text>
								</paragraph><paragraph id="H0A0F91E582E94BAD9D00123DD3B6C770"><enum>(8)</enum><text>other research as
				determined appropriate by the Director of the Institute, the Alzheimer’s
				Disease Centers and Alzheimer’s Disease Research Centers established under
				section 445.</text>
								</paragraph></subsection><subsection id="HBBFB719F5B814993928B3BA773FAEB67"><enum>(b)</enum><header>Early Diagnosis
				and Detection Research</header>
								<paragraph id="H1915B323F05941F8A481F46C90BC43E3"><enum>(1)</enum><header>In
				general</header><text>The Director of the Institute, in consultation with the
				directors of other relevant institutes and centers of the National Institutes
				of Health, shall conduct, or make grants for the conduct of, research related
				to the early detection, diagnosis, and prevention of Alzheimer’s disease and of
				mild cognitive impairment or other potential precursors to Alzheimer’s
				disease.</text>
								</paragraph><paragraph id="H339CBEFC17754A9FBF5E94E49C7F0D3"><enum>(2)</enum><header>Evaluation</header><text>The
				research described in paragraph (1) may include the evaluation of diagnostic
				tests and imaging techniques.</text>
								</paragraph><paragraph id="H0A608891E8AA4BF4A903057166F2AD2B"><enum>(3)</enum><header>Study</header><text>Not
				later than 1 year after the date of enactment of this section, the Director of
				the Institute, in cooperation with the heads of other relevant Federal
				agencies, shall conduct a study, and submit to Congress a report, to estimate
				the number of individuals with early-onset Alzheimer’s disease (those diagnosed
				before the age of 65) and related dementias in the United States, the causes of
				early-onset dementia, and the unique problems faced by such individuals,
				including problems accessing government services.</text>
								</paragraph></subsection><subsection id="HFD5559518AA649F69421B74D6BD6691E"><enum>(c)</enum><header>Vascular
				Disease</header><text>The Director of the Institute, in consultation with the
				directors of other relevant institutes and centers of the National Institutes
				of Health, shall conduct, or make grants for the conduct of, research related
				to the relationship of vascular disease and Alzheimer’s disease, including
				clinical trials to determine whether drugs developed to prevent cerebrovascular
				disease can prevent the onset or progression of Alzheimer’s disease.</text>
							</subsection><subsection id="HCFAA656FBBC74DBEAA49D54DFB368FA2"><enum>(d)</enum><header>Treatments and
				prevention</header><text>The Director of the Institute shall place special
				emphasis on expediting the translation of research findings under this section
				into effective treatments and prevention strategies for at-risk
				individuals.</text>
							</subsection><subsection id="HDAC565C49B1F4FC8A79400FBC75E7556"><enum>(e)</enum><header>National
				Alzheimer’s Coordinating Center</header><text>The Director of the Institute may
				establish a National Alzheimer’s Coordinating Center to facilitate
				collaborative research among the Alzheimer’s Disease Centers and Alzheimer’s
				Disease Research Centers established under section
				445.</text>
							</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
				</subsection><subsection id="HB66168A2E66C419E891851D0FAE1C3F4"><enum>(b)</enum><header>Alzheimer’s
			 Disease Centers</header><text>Section 445(a)(1) of the
			 <act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
			 285e–2(a)(1)) is amended by inserting <quote>, and outcome measures and disease
			 management,</quote> after <quote>treatment methods</quote>.</text>
				</subsection></section><section id="H0A665E49920B4DE08734E22704060585"><enum>105.</enum><header>Research on
			 Alzheimer’s disease caregiving</header><text display-inline="no-display-inline">Section 445C of the
			 <act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
			 285e–5) is amended—</text>
				<paragraph id="HC3E2938766A049CF823F86530000DB26"><enum>(1)</enum><text>by striking
			 <quote><header-in-text level="subsection" style="OLC">Sec.</header-in-text>
			 445C. (a)</quote> and inserting the following:</text>
					<quoted-block id="H9FC77D198A8F4A4C92A35812339279D0" style="OLC">
						<section id="H6D44CAA0E7504CC7A4546DDC561B2DD4"><enum>445C.</enum><header>Research on
				Alzheimer’s disease services and caregiving</header>
							<subsection id="HCB2F97B506D643F797F7E6DD9DFF0008"><enum>(a)</enum><header>Services
				Research</header>
							</subsection></section><after-quoted-block>;</after-quoted-block></quoted-block>
				</paragraph><paragraph id="HF6791F7B9BF4434CB79D1E4B5D14C044"><enum>(2)</enum><text>by striking
			 subsections (b), (c), and (e);</text>
				</paragraph><paragraph id="H6A505D5663784CC694D5F299B398A4A4"><enum>(3)</enum><text>by inserting after
			 subsection (a) the following:</text>
					<quoted-block id="H851398D137504C7CB32FFF00918CAA50" style="OLC">
						<subsection id="H46620D5661A04FF299B631E8E2B19C4B"><enum>(b)</enum><header>Interventions
				Research</header><text>The Director shall, in collaboration with the directors
				of the other relevant institutes and centers of the National Institutes of
				Health, conduct, or make grants for the conduct of, clinical, social, and
				behavioral research related to interventions designed to help caregivers of
				patients with Alzheimer’s disease and related disorders and improve patient
				outcomes.</text>
						</subsection><after-quoted-block>;
				and</after-quoted-block></quoted-block>
				</paragraph><paragraph id="H2539A362113A43E587FD00CB6EBF32A6"><enum>(4)</enum><text>in subsection (d)
			 by striking <quote>(d) the Director</quote> and inserting <quote>(c)
			 <header-in-text level="subsection" style="OLC">Model curricula and
			 techniques</header-in-text>.—The Director</quote>.</text>
				</paragraph></section><section id="HE693397D52D6437C95CA785CBFC0C863"><enum>106.</enum><header>National summit
			 on alzheimer's disease</header>
				<subsection id="H0C6D36C4DB5D480F0053CD504227F97E"><enum>(a)</enum><header>In
			 General</header><text>Not later than 3 years after the date of enactment of
			 this Act, and every 3 years thereafter, the Secretary of Health and Human
			 Services (referred to in this section as the <quote>Secretary</quote>) shall
			 convene a summit of researchers, representatives of academic institutions,
			 Federal and State policymakers, public health professionals, and
			 representatives of voluntary health agencies to provide a detailed overview of
			 current research activities at the National Institutes of Health, as well as to
			 discuss and solicit input related to potential areas of collaboration between
			 the National Institutes of Health and other Federal health agencies, including
			 the Centers for Disease Control and Prevention, the Administration on Aging,
			 the Agency for Healthcare Research and Quality, and the Health Resources and
			 Services Administration, related to research, prevention, and treatment of
			 Alzheimer’s disease.</text>
				</subsection><subsection id="HAA7872E89DB34AB39CE09C2D79C9E9AA"><enum>(b)</enum><header>Focus
			 Areas</header><text>The summit convened under subsection (a) shall focus
			 on—</text>
					<paragraph id="HE6CDE5C5E8EA487DB4073DC02CE857DE"><enum>(1)</enum><text>a
			 broad range of Alzheimer’s disease research activities relating to biomedical
			 research, prevention research, and caregiving issues;</text>
					</paragraph><paragraph id="H3EADA97A92BD461F9DAEAE3932CF0043"><enum>(2)</enum><text>clinical research
			 for the development and evaluation of new treatments for the disease;</text>
					</paragraph><paragraph id="HBCB14E1E99AF490EB48100AC74B05052"><enum>(3)</enum><text>translational
			 research on evidence-based and cost-effective best practices in the treatment
			 and prevention of the disease;</text>
					</paragraph><paragraph id="HC99B22F4F48A4DD2B259BF3618E8863F"><enum>(4)</enum><text>information and
			 education programs for health care professionals and the public relating to the
			 disease;</text>
					</paragraph><paragraph id="H826D8089FFBC4615B756C01DA8CD3B85"><enum>(5)</enum><text>priorities among
			 the programs and activities of the various Federal agencies regarding such
			 diseases; and</text>
					</paragraph><paragraph id="HD242567A492843BFBE6BCB6D8CDAEBDB"><enum>(6)</enum><text>challenges and
			 opportunities for scientists, clinicians, patients, and voluntary organizations
			 relating to the disease.</text>
					</paragraph></subsection><subsection id="H1B177E2DB3D44AAFAED9B200AEF049DD"><enum>(c)</enum><header>Report</header><text>Not
			 later than 180 days after the date on which the National Summit on Alzheimer’s
			 Disease is convened under subsection (a), the Director of National Institutes
			 of Health shall prepare and submit to the appropriate committees of Congress a
			 report that includes a summary of the proceedings of the summit and a
			 description of Alzheimer’s research, education, and other activities that are
			 conducted or supported through the national research institutes.</text>
				</subsection><subsection id="H3E786FE4B4454534AFDC1262FFF7D00"><enum>(d)</enum><header>Public
			 Information</header><text>The Secretary shall make readily available to the
			 public information about the research, education, and other activities relating
			 to Alzheimer’s disease and other related dementias, conducted or supported by
			 the National Institutes of Health.</text>
				</subsection></section></title><title id="HD77778C6109A48348C95CBC71E01865B"><enum>II</enum><header>Public health
			 promotion and prevention of Alzheimer's disease</header>
			<section id="HF647625B6DCB494493B900FC2BFC67BE"><enum>201.</enum><header>Enhancing
			 public health activities related to cognitive health, Alzheimer's disease, and
			 other dementia's</header><text display-inline="no-display-inline">Part P of
			 title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/280g">42 U.S.C. 280g et seq.</external-xref>) is amended
			 by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H880386211AB04FE38CD70363F8DDCFCE" style="OLC">
					<section id="H198BFF3749354701BDFF0165E069762B"><enum>399R.</enum><header>Alzheimer's
				disease public education campaign</header>
						<subsection id="H270363D09F6F48328E95007F4EC420FA"><enum>(a)</enum><header>In
				general</header><text>The Secretary, acting through the Director of the Centers
				for Disease Control and Prevention, shall directly or through grants,
				cooperative agreements, or contracts to eligible entities, conduct, support,
				and promote the coordination of research, investigations, demonstrations,
				training, and studies relating to the control, prevention, and surveillance of
				the risk factors associated with cognitive health, Alzheimer’s disease, and
				other dementias, and seek early recognition and intervention in the course of
				Alzheimer’s disease and other dementias.</text>
						</subsection><subsection id="H1D65B88F77EC46108458DA6071C7F3CE"><enum>(b)</enum><header>Certain
				activities</header><text>Activities under subsection (a) shall include—</text>
							<paragraph id="HFF08870811874952A554C0A42CDE49"><enum>(1)</enum><text>providing support
				for the dissemination and implementation of the Roadmap to Maintaining
				Cognitive Health to effectively mobilize the public health community into
				action;</text>
							</paragraph><paragraph id="H84E7973790F8430A9F121E20A2EFA60"><enum>(2)</enum><text>the development of
				coordinated public education programs, services, and demonstrations which are
				designed to increase general awareness of cognitive function and promote a
				brain healthy lifestyle;</text>
							</paragraph><paragraph id="H0034C59908B34918A4F3D8F0DE980000"><enum>(3)</enum><text>the development of
				targeted communication strategies and tools to educate health professionals and
				service providers about the early recognition, diagnosis, care, and management
				of Alzheimer's disease and dementia, and to provide consumers with information
				about interventions, products, and services that promote cognitive health and
				assist consumers in maintaining current understanding about cognitive health
				based on the best science available; and</text>
							</paragraph><paragraph id="HBBAC2433F8FA4A1FA3F272BCDD3D8399"><enum>(4)</enum><text>provide support
				for the collection, publication, and analysis of data on the prevalence and
				incidence of cognitive health, Alzheimer's disease, and other dementias, and
				the evaluation of existing population-based surveillance systems (such as the
				Behavioral Risk Factors Surveillance Survey (BRFFS) and the National Health
				Interview Survey (NHIS)) to identify limitations that exist in the area of
				cognitive health, and if necessary, the development of a surveillance system
				for cognitive decline, including Alzheimer's disease and dementia.</text>
							</paragraph></subsection><subsection id="HEFBBCC4B1A864C64A55700D7C9A7BDD"><enum>(c)</enum><header>Grants</header><text>The
				Secretary may award grants under this section—</text>
							<paragraph id="H7BBED1B553BA43BAA7259508EB967B6E"><enum>(1)</enum><text>to State and local
				health agencies for the purpose of—</text>
								<subparagraph id="HDBF9053C6D4B4B848717D220CF9E6D14"><enum>(A)</enum><text>coordinating
				activities related to cognitive health, Alzheimer's disease, and other
				dementias with existing State-based health programs and community-based
				organizations;</text>
								</subparagraph><subparagraph id="HA0FCFAD58B3149C892AAB1EB43BF9CF9"><enum>(B)</enum><text>providing
				Alzheimer's disease education and training opportunities and programs for
				health professionals; and</text>
								</subparagraph><subparagraph id="H4BAC1AC26BDA4EF4AFF37983B061473F"><enum>(C)</enum><text>developing,
				testing, evaluating, and replicating effective Alzheimer's disease intervention
				programs to maintain or improve cognitive health; and</text>
								</subparagraph></paragraph><paragraph id="HF1FFE7DE34A94E32A983EA1377CA6837"><enum>(2)</enum><text>to nonprofit
				private health organizations with expertise in providing care and services to
				individuals with Alzheimer’s disease for the purpose of—</text>
								<subparagraph id="H6B6FEC954CF94E949FDDCB4CB56D26CF"><enum>(A)</enum><text>disseminating
				information to the public;</text>
								</subparagraph><subparagraph id="H9A9C9461228D43D28233234EF6DCEE82"><enum>(B)</enum><text>testing model
				intervention programs to improve cognitive health; and</text>
								</subparagraph><subparagraph id="H0E6DE30D4F84409F0022D29BFE7CFEBC"><enum>(C)</enum><text>coordinating
				existing services with State-based health programs.</text>
								</subparagraph></paragraph></subsection><subsection id="H524D93A3F8C6457E87EEA500EA974034"><enum>(d)</enum><header>Authorization of
				appropriations</header><text>For the purpose of carrying out this section,
				there are authorized to be appropriated $15,000,000 for fiscal year 2008, and
				such sums as may be necessary for each of fiscal years 2009 through
				2012.</text>
						</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</section></title><title id="H4B696F7BF24D4761A3897E8CCAB10116"><enum>III</enum><header>Assistance for
			 caregivers</header>
			<section id="H9BBDB15BD29043FEA2F0334D924C8D15"><enum>301.</enum><header>Alzheimer's
			 disease call center</header><text display-inline="no-display-inline">Part P of
			 title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/280g">42 U.S.C. 280g et seq.</external-xref>), as amended
			 by section 201, is further amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H34135CC3F79B4FE58363ED00621EBC2F" style="OLC">
					<section id="HBB20B159792B4BF79E1500B16E4EC74D"><enum>399S.</enum><header>Alzheimer's
				disease call center</header>
						<subsection id="HDCAC65108BD6414A875086A01CA6E898"><enum>(a)</enum><header>In
				general</header><text>The Secretary, acting through the Administration on
				Aging, shall award a cooperative grant to a non-profit or community-based
				organization to support the establishment and operation of an Alzheimer’s Call
				Center that is accessible 24 hours a day, 7 days a week, to provide expert
				advice, care consultation, information, and referrals nationwide at the
				national and local level regarding Alzheimer's disease.</text>
						</subsection><subsection id="HCFD22DC1A0224759A42B884EE68E822"><enum>(b)</enum><header>Activities</header><text>The
				Alzheimer’s Call Center established under subsection (a) shall—</text>
							<paragraph id="H702EAEC8044E40FFA6DDA474978D33D9"><enum>(1)</enum><text>collaborate with
				the Administration on Aging in the development, modification, and execution of
				the Call Center’s work plan;</text>
							</paragraph><paragraph id="H44AE41193E354EC394E191F5DFB32A3"><enum>(2)</enum><text>assist the
				Administration on Aging in developing and sustaining collaborations between the
				Alzheimer’s Call Center, the Eldercare Locator, the grantees under the
				Alzheimer’s Demonstration Program, and the Aging Network;</text>
							</paragraph><paragraph id="H316C4A47A6ED453EA4321937DAE8008B"><enum>(3)</enum><text>provide a 24-hour
				a day, 7-days a week toll-free Call Center with trained professional staff who
				are available to provide care consultation and crisis intervention to
				individuals with Alzheimer’s disease and other dementias, their family and
				informal caregivers, and others as appropriate;</text>
							</paragraph><paragraph id="H2AC8756B5CAA453387B25EBB1FE269E"><enum>(4)</enum><text>be accessible by
				telephone through a single 1–800 telephone number, website, and e-mail address;
				and</text>
							</paragraph><paragraph id="H5267C4206E814EA497D1325DE22700A4"><enum>(5)</enum><text>evaluate the
				impact of the Call Center’s activities and services.</text>
							</paragraph></subsection><subsection id="H2B4C37D36AAC452700347EAC2B2704B4"><enum>(c)</enum><header>Multilingual
				capacity</header><text>The Call Center established under this section shall
				have a multilingual capacity and shall respond to inquiries in at least 140
				languages through its own bilingual staff and with the use of a language
				translation service.</text>
						</subsection><subsection id="H75E4779CB8C441C0BFB66BC6DF63D600"><enum>(d)</enum><header>Response to
				emergency and ongoing needs</header><text>The Call Center established under
				this section shall collaborate with community-based organizations, including
				non-profit agencies and organizations, to ensure local, on-the-ground capacity
				to respond to emergency and on-going needs of Alzheimer’s patients, their
				families, and informal caregivers.</text>
						</subsection><subsection id="H33402E8E96B543ADA513A93DB618286E"><enum>(e)</enum><header>Authorization of
				appropriations</header><text>For the purpose of carrying out this section,
				there are authorized to be appropriated $1,000,000 for fiscal year 2008, and
				such sums as may be necessary for each of fiscal years 2009 through
				2012.</text>
						</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</section><section id="HEBD8CA1EFA1F411DAE097B521617A4BF"><enum>302.</enum><header>Innovative
			 Alzheimer's care State matching grant program</header>
				<subsection id="H63362404636A4B1BB7FC5374CAB1F"><enum>(a)</enum><header>Authorization of
			 appropriations</header><text display-inline="yes-display-inline">Section
			 398B(e) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/280c-5">42 U.S.C. 280c–5(e)</external-xref>) is
			 amended—</text>
					<paragraph id="H74A2FF031DA8491CB5303F6CF5BD088E"><enum>(1)</enum><text display-inline="yes-display-inline">by striking <quote>and such</quote> and
			 inserting <quote>such</quote>; and</text>
					</paragraph><paragraph id="HC667065F6C9F4839B1448CCCAC7B071E"><enum>(2)</enum><text display-inline="yes-display-inline">by inserting before the period the
			 following: <quote>, $25,000,000 for fiscal year 2008, and such sums as may be
			 necessary for each of fiscal years 2009 through 2012</quote>.</text>
					</paragraph></subsection><subsection id="HC4F00767BBCD4521A0D3E26204FF2D47"><enum>(b)</enum><header>Program
			 expansion</header><text>Section 398(a) of the Public Health Service Act (42
			 U.S.C. 280c–3(a))</text>
					<paragraph id="H5C5C5D0F6284427488CAA7E52D6F5808"><enum>(1)</enum><text>in paragraph (2),
			 by inserting after <quote>other respite care</quote> the following: <quote>and
			 care consultation including assessment of needs, assistance with planning and
			 problem solving and providing supportive listening</quote>;</text>
					</paragraph><paragraph id="H172F599A6013468589B160D84D1EBFFA"><enum>(2)</enum><text>in paragraph (3),
			 by striking <quote>; and</quote> and inserting the following: <quote>, and
			 individuals in frontier areas (as defined as areas with 6 or fewer people per
			 square mile or areas in which it takes people at least 60 minutes or 60 miles
			 to reach a market or service area);</quote>;</text>
					</paragraph><paragraph id="H14856BAB83A14A89A51CC394A8976DAE"><enum>(3)</enum><text>in paragraph (4),
			 by striking the period at the end and inserting a semicolon; and</text>
					</paragraph><paragraph id="H45093AD4F3234EEEB9F335DC9986EC48"><enum>(4)</enum><text>by adding at the
			 end the following:</text>
						<quoted-block display-inline="no-display-inline" id="H5C83435206194A278D76C4404C75B1AD" style="OLC">
							<paragraph id="HA73B8764E1744F4485864E9342722F47"><enum>(5)</enum><text>to encourage
				grantees under this section to coordinate activities with other State officials
				administering efforts to promote long-term care options that enable older
				individuals to receive long-term care in home- and community-based settings, in
				a manner responsive to the needs and preferences of older individuals and their
				family caregivers;</text>
							</paragraph><paragraph id="H980D48FCC8ED44278FED00E99BD0B7B1"><enum>(6)</enum><text>to encourage
				grantees under this section to—</text>
								<subparagraph id="HD8B5F817545C424A8634F8006B43B8E1"><enum>(A)</enum><text>engage in
				activities that support early detection and diagnosis of Alzheimer’s disease
				and related dementia;</text>
								</subparagraph><subparagraph id="HC850466CF148479398947029922766DA"><enum>(B)</enum><text>provide training
				to medical personnel including hospital staff, emergency room personnel, home
				health care workers and physician office staff, rehabilitation services
				providers, and caregivers about how Alzheimer’s can affect behavior and impede
				communication in medical and community settings;</text>
								</subparagraph><subparagraph id="H08251692DE54419DA8FEB1AFD751E638"><enum>(C)</enum><text>develop guidelines
				to provide the medical community with up-to-date information about the best
				methods of care for individuals with Alzheimer’s disease;</text>
								</subparagraph><subparagraph id="HBF2F96403E5B4BFB8767B81415A4E946"><enum>(D)</enum><text>inform community
				physicians about available resources to assist them in detecting and managing
				Alzheimer’s; and</text>
								</subparagraph><subparagraph id="HE84162E6A8124EA9A6A7E0397079D34"><enum>(E)</enum><text>raise awareness
				among community physicians about the availability of community-based
				organizations which can assist individuals with Alzheimer’s and their
				caregivers;</text>
								</subparagraph></paragraph><paragraph id="HDB2A5EC4FA7046F1A97493FF5E87CB8"><enum>(7)</enum><text>to encourage
				grantees under this section to engage in activities that use findings from
				evidence-based research on service models and techniques to support individuals
				with Alzheimer’s disease and their caregivers; and</text>
							</paragraph><paragraph id="H7D112289C3764F94BAFC002E0008EBF"><enum>(8)</enum><text>to encourage
				grantees under this section to incorporate best practices for effectively
				serving individuals with Alzheimer’s disease in community-based settings into
				ongoing State systems change and long-term care
				activities.</text>
							</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph></subsection></section></title></legis-body>
</bill>


